Опыт лечения тяжелой лихорадки денге препаратом риамиловир

Abstract

The article presents the experience of using riamilovir in the treatment of a case of severe dengue fever. It describes a case of severe form of dengue fever in a tourist who returned from Thailand and was hospitalized in the State Budgetary Institution Infectious Clinical Hospital No 2 in Moscow and the successful use of off-label nucleoside analogue riamilovir to treat the patient. A patient with dengue fever confirmed by detection of IgM to dengue virus (DV) and DV RNA in serum had widespread petechial rash and profuse uterine bleeding on the 5th day of the disease, and developed thrombocytopenia up to 70·109 cells/liter. A second DV infection was suspected. On the same day, serum examination revealed high titer IgG to DV, and DV genotyping was performed (virus genotype I was detected). The patient's condition was considered as repeated DV infection, development of severe form of infection. Based on the data on the successful use of the nucleoside analog riamilovir for the treatment of classical dengue fever by Russian specialists in the Republic of Guinea, a council of specialists at the medical board decided to use the “off-label” drug to treat the patient. Within a day after the start of therapy, the symptoms of the disease began to regress and on the 10th day of the disease the patient was discharged from the hospital in satisfactory condition. The obtained positive experience of using the nucleoside analog Riamilovir in real clinical practice in the treatment of a patient with severe form of dengue fever opens new opportunities for the treatment of this infection. Full-scale clinical trials of this drug are needed to evaluate the possibility of including a new indication for use. Key words: Dengue fever, severe form, Riamilovir, antiviral therapy, vector-borne viral infections